Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Neuroendocrine Tumors 12 Neoplasms 8 Carcinoid Tumor 7 Diarrhea 6 Colorectal Neoplasms 6 Carcinoma, Hepatocellular 6 Breast Neoplasms 5 Acromegaly 5 Vipoma 4 Stomach Neoplasms 4 Somatostatinoma 4 Rectal Neoplasms 4 Insulinoma 4 Glucagonoma 4 Gastro-enteropancreatic neuroendocrine tumor 4 Esophageal Neoplasms 4 Carcinoma, Islet Cell 4 Adenoma, Islet Cell 4 Weight Loss 3 Prostatic Neoplasms 3 Pancreatic Neoplasms 3 Neoplasm Metastasis 3 Intestinal Obstruction 3 Gastrinoma 3 Colonic Neoplasms 3 Carcinoma 3 Thymoma 2 Pituitary Neoplasms 2 Ovarian Neoplasms 2 Meningioma 2

Interventions

Colonoscopy 19 Water 3 Aspirin 3 Ursodeoxycholic Acid 2 Sunitinib 2 Occult Blood 2 Narrow Band Imaging 2 Folic Acid 2 Endoscopic Mucosal Resection 2 Calcium Carbonate 2 pegvisomant 1 gadolinium ethoxybenzyl DTPA 1 defactinib 1 S-Adenosylmethionine 1 Reference Standards 1 Polyethylene Glycols 1 Octreotide 1 Methods 1 Mesalamine 1 Mass Screening 1 Injections 1 Indocyanine Green 1 Gastroscopy 1 Endoscopy 1 Early Detection of Cancer 1 Drug Evaluation 1 Diet, Fat-Restricted 1 Diagnostic Tests, Routine 1 Cholecystectomy 1 Cholecalciferol 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Adenoma × Octreotide × Clear all

NCT02032784 2020-07-16

Prophylactic Octreotide to Prevent Post Duodenal EMR and Ampullectomy Bleeding

AdventHealth

Phase 4 Terminated

Adenoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡